β2 adrenergic receptor (β2-AR) antagonist alleviates ischemia-induced BBB injury by inhibiting HIF-1α expression and decreasing VEGF upregulation and the secretion of VEGF and MMP-2 [60]. The gene discussed is VEGFA; the disease is ischemia.